Self-collected vaginal samples to estimate endometrial cancer risk in women with abnormal bleeding
Studies self-collected vaginal samples to predict endometrial cancer risk in people with abnormal uterine bleeding.
Plain-language title generated from the registry record
Registry title: Detection of Endometrial Cancer Through Risk Modelling
Key facts
- Where
- Vancouver, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 40 and older with unexplained abnormal uterine bleeding, who still have their uterus and are referred for an endometrial biopsy.
- Age
- 40 years and older
- Sex
- Women only
- Disease stage
- Unexplained abnormal uterine bleeding (not caused by an IUD or similar) being checked with an endometrial biopsy.
- Earlier treatment
- Cannot have started hormone therapy (HRT, birth control, IUD) in the past year, except tamoxifen. Cannot have had pelvic radiation in the past 3 months.
Main reasons for not taking part
- Endometrial sampling, pelvic radiation, or vaginal infection (vaginosis, yeast) in the past 3 months
- Started hormone therapy (HRT, birth control, IUD) in the past year, except tamoxifen
- Intercourse, vaginal product use, or douching in the past 48 hours
- For the follow-up part: endometrial cancer or EIN, or a hysterectomy advised
Read by machine on 12 November 2026.
Where in Canada
- VGH Research PavilionVancouver, CanadaContact: Aline Talhouk, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of British Columbia
- Trial code
- NCT06268626
- Record updated
- 16 April 2026
- Original description
The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention.Read full original descriptionShow less
Non-Invasive Strategies for Early Detection of Uterine Cancer in Patients With Abnormal Uterine Bleeding
The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention.
This two-part case-cohort prospective study will recruit patients whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Participants will complete an online health questionnaire, and a subset will be invited to self-collect vaginal samples for sequencing.
Selected sequenced participants will be invited for longitudinal monitoring (questionnaires, wearable fitness tracker) and an additional vaginal self-collection to identify persistent genetic mutations or microbiome alterations 6-8 months later.
Inclusion: Study Part A:; 40 years and older; Experiencing unexplained abnormal uterine bleeding (i.e., not from IUD, etc.); Have an intact uterus; Referred for an endometrial biopsy; Study Part B/Longitudinal monitoring:; Those selected for sequencing (from Part A) and who retained their uterus.
Exclusion: Started hormone therapy (HRT, birth control, IUD) in the past year (with the exception of tamoxifen); Endometrial sampling, pelvic radiation, or vaginal infection (vaginosis, yeast) in the past 3 months; Study Part A:; Intercourse, vaginal product use, or douching in the past 48 hours; Study Part B/Longitudinal monitoring:; Same as Study Part A; EC or EIN, or anyone who is recommended a hysterectomy.